Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Northern Europe Keeps Up The Pressure On Biosimilar Infliximab Switching

This article was originally published in Scrip

Executive Summary

Northern European efforts to boost the use of biosimilar infliximab rather than Janssen's Remicade are gathering pace, with the Norwegian NOR-SWITCH study having been extended by 26 weeks to complete the switch from Remicade to Celltrion's biosimilar, Remsima, and a number of similar studies being conducted by both industry and non-commercial sponsors in the Netherlands.

Advertisement

Related Content

Remsima Stars In Orion Pharma’s First Half

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register